Filing Flows › Camp4 Therapeutics (CAMP) › Q2 2026
Camp4 Therapeutics (CAMP) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Camp4 Therapeutics (CAMP) reported revenue of $1.8M for the second quarter 2026 (Q2 2026), +19% from a year earlier and +37% from the quarter before. Operating margin was -752.1%.
Camp4 Therapeutics, Q2 2026: revenue $1.8M (+19% year over year), operating margin -752.1%, net loss $33.5M, operating cash flow −$12.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.8M | +37% | +19% |
| Operating profit | −$13.4M | — | — |
| Net earnings | −$33.5M | — | — |
| Operating cash flow | −$12.7M | — | — |
What changed
Revenue was $1.8M in Q2 2026, up 19% year over year and up 37% from the previous quarter.
Operating costs exceeded revenue by $13.4M, an operating margin of -752.1%. Total costs grew 4% against revenue growth of 19%. The quarter ended with a net loss of $33.5M, wider than the previous quarter's $18.3M loss. Net interest and other expense of $20.1M was the main reason.
Operating cash flow was −$12.7M. Non-cash charges added back $515K of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items added $18.4M. Capital expenditures of $129K exceeded it, leaving free cash flow of −$12.8M.
Questions
What was Camp4 Therapeutics' revenue in the second quarter 2026?
Camp4 Therapeutics (CAMP) reported revenue of $1.8M for the second quarter 2026 (Q2 2026), +19% from a year earlier and +37% from the quarter before.
Was Camp4 Therapeutics profitable in the second quarter 2026?
Operating loss was $13.4M (-752.1% of revenue) and net loss $33.5M.
Source: Camp4 Therapeutics 10-Q on SEC EDGAR.